Department of Dermatology and Allergy, Hannover Skin Cancer Center, Hannover Medical School.
Dtsch Arztebl Int. 2012 Feb;109(8):133-40. doi: 10.3238/arztebl.2012.0133. Epub 2012 Feb 24.
Many new antitumor drugs have been approved in recent years. Their side-effect profiles are distinct from those of older drugs, and their adverse effects are sometimes highly specific, particularly with respect to the skin.
This article is based on articles retrieved by a selective search in Medline and the database of the American Society of Clinical Oncology (ASCO), as well as on the authors' personal experience.
Cutaneous adverse effects are among the more common adverse effects of new antitumor drugs: they occur in up to 34% of patients receiving multikinase inhibitors, up to 90% of those receiving selective tyrosine kinase inhibitors (such as EGFR or mutant BRAF inhibitors), and up to 68% of those receiving immunotherapeutic agents (such as CTLA4 inhibitors). These adverse effects can be correlated with therapeutic benefit, but they can also be treatment-limiting because of their severity or visibility.
The recognition and proper management of cutaneous adverse effects is an important part of treatment with new antitumor drugs.
近年来，许多新型抗肿瘤药物已获得批准。它们的副作用谱与旧药物不同，其不良反应有时具有高度特异性，尤其是在皮肤方面。
本文基于在 Medline 和美国临床肿瘤学会（ASCO）数据库中进行选择性搜索获得的文章，以及作者的个人经验。
皮肤不良反应是新型抗肿瘤药物较常见的不良反应之一：接受多激酶抑制剂治疗的患者中，多达 34%出现皮肤不良反应，接受选择性酪氨酸激酶抑制剂（如 EGFR 或突变 BRAF 抑制剂）治疗的患者中，多达 90%出现皮肤不良反应，接受免疫治疗药物（如 CTLA4 抑制剂）治疗的患者中，多达 68%出现皮肤不良反应。这些不良反应可能与治疗获益相关，但也可能因严重程度或可见性而限制治疗。
识别和正确管理皮肤不良反应是新型抗肿瘤药物治疗的重要组成部分。
